Dosage protocol · Growth Hormone & Performance
Tesamorelin 20 mg
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
- Reconstitute: Add 3.0 mL bacteriostatic water per 20 mg vial → ~6.67 mg/mL concentration.
- Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.
BAC water3.0mL
Concentration6.67mg/mL
Reconstitution
Tesamorelin dosage chart
Tesamorelin dosage chart
| Week | Dose | Draw |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 15 units0.15 mL |
| Weeks 2–12+ | 2 mg / 2000 mcg | 30 units0.30 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to release growth hormone.[1] Rather than replacing growth hormone directly, it works upstream, prompting the pituitary to produce more of it.
In the US, tesamorelin is marketed as the prescription drug EGRIFTA SV, with an FDA-approved indication limited to reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat redistribution linked to HIV and antiretroviral therapy.[2] That approval is narrow: it does not cover general weight loss, bodybuilding, anti-aging, or cosmetic use, and the label states tesamorelin is not indicated for weight-loss management.
Benefits & side effects
The core evidence is a randomized trial published in the New England Journal of Medicine, which found tesamorelin reduced visceral adipose tissue in HIV-positive adults with abdominal fat accumulation compared with placebo — the data underlying FDA approval.[3] Imaging methods such as CT and MRI distinguished visceral fat from subcutaneous and liver fat, since a change in one compartment does not necessarily track with overall body weight.
Beyond the approved indication, trials in JAMA and The Lancet HIV examined tesamorelin's effect on liver fat in HIV-positive adults and reported reductions in hepatic fat.[4] These findings are promising but investigational; tesamorelin is not FDA-approved for fatty liver disease, and visceral-fat reductions have not been shown to persist after stopping treatment. Claims about muscle gain, performance, or anti-aging go well beyond what this evidence supports.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
1
Reconstitution
mg
mL
Concentration—
Per unit (0.01 mL)—
Per 10 units (0.1 mL)—
2
Your dose
Doses per vial—
Vial lasts—
Draw to
— units
=
—
